Business Standard

Vaccine leadership, not chauvinism

The WHO's initiative to provide equitable access to vaccines - COVAX - is devoid of the funds needed to procure and supply the shots to poorer countries.

Coronavirus, vaccine, covid, drugs, clinical trials
Premium

Covaxin is based on highly purified and inactivated two-dose Sars-Cov-2 vaccine manufactured in a vero cell manufacturing platform

Sunita Narain
Exactly one year later, the world is moving towards the next decisive phase in the fight against Covid-19. Vaccines are now available and people are being inoculated — many rich countries have set targets for full immunisation by mid-year. With this done, they say, it can be back to business.

But for this to happen, we need a hard introspection by our scientific and political leadership during this critical phase of recovery. Today, on the one hand, the virus is mutating and becoming more unpredictable and there is still too much that we do not know. For instance, it is not
Disclaimer: These are personal views of the writer. They do not necessarily reflect the opinion of www.business-standard.com or the Business Standard newspaper

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in